Literature DB >> 16604382

Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.

.   

Abstract

PURPOSE: To prospectively determine the incidence of a latanoprost-induced increase in iris pigmentation in Japanese brown iris eyes by identifying changes in iris pigmentation on a series of iris color photographs.
METHODS: In a cohort study, we prospectively and consecutively enrolled 104 patients (104 eyes) with primary open-angle glaucoma or normal-tension glaucoma who began treatment with latanoprost eye drops for the first time. None of the enrolled patients had a history of previous intraocular surgery or laser surgery. Patients comprised 51 men and 53 women. Their ages ranged from 23 to 80 years (mean +/- SD, 63.8 +/- 10.4 years). Before and every 3 months after starting latanoprost treatment, iris photographs were taken using a slit-lamp biomicroscope with an attached camera. To identify an increase in iris pigmentation, seven glaucoma specialists independently read the series of photographs. If five of the seven observers agreed that iris pigmentation had increased, we determined that the iris pigmentation had increased from the time the previous photograph was taken. Ten normal volunteers served as controls, and photographs of their eyes were used in the evaluation of iris pigmentation. The Kaplan-Meier life table analysis was adopted to evaluate the incidence of increase in iris pigmentation during treatment with latanoprost.
RESULTS: The Kaplan-Meier life table analysis indicated that the incidence of increased iris pigmentation at 3, 6, 9, 12, and 15 months after the start of latanoprost treatment was 16.3%, 34.2%, 49.5%, 58.2%, and 58.2%, respectively.
CONCLUSIONS: Latanoprost instillation for at least 1 year induced increased iris pigmentation in approximately 50% of the treated Japanese eyes, which is a considerably higher percentage than that reported in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604382     DOI: 10.1007/s10384-005-0288-7

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  11 in total

1.  The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.

Authors:  I Grierson; W R Lee; D M Albert
Journal:  Arch Ophthalmol       Date:  1999-03

2.  [Increased iris pigmentation after use of latanoprost in Japanese brown eyes].

Authors:  T Hara
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2001-05

3.  Analysis of irises with a latanoprost-induced change in iris color.

Authors:  Esther Arranz-Marquez; Miguel A Teus; M Antonia Saornil; M Carmen Mendez; Raquel Gil
Journal:  Am J Ophthalmol       Date:  2004-10       Impact factor: 5.258

4.  Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.

Authors:  T Chiba; K Kashiwagi; S Kogure; K Abe; T Shibuya; M Furuichi; H Iijima; S Tsukahara
Journal:  J Glaucoma       Date:  2001-10       Impact factor: 2.503

5.  Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.

Authors:  J C Tsai; J A Sivak-Callcott; B G Haik; J Zhang; I W McLean
Journal:  J Glaucoma       Date:  2001-10       Impact factor: 2.503

6.  The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

Authors:  P J Wistrand; J Stjernschantz; K Olsson
Journal:  Surv Ophthalmol       Date:  1997-02       Impact factor: 6.048

7.  A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.

Authors:  Daniel M Albert; Ronald E Gangnon; Michele L Zimbric; Christine M Damico; Marian R Fisher; Joel Gleiser; Hans E Grossniklaus; W Richard Green
Journal:  Arch Ophthalmol       Date:  2004-11

8.  A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.

Authors:  Albert Alm; John Schoenfelder; Jacquie McDermott
Journal:  Arch Ophthalmol       Date:  2004-07

9.  Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.

Authors:  S-Y Chou; C-K Chou; T-M Kuang; W-M Hsu
Journal:  Eye (Lond)       Date:  2005-07       Impact factor: 3.775

10.  A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.

Authors:  Tatsuya Chiba; Kenji Kashiwagi; Kiyotaka Ishijima; Mieko Furuichi; Satoshi Kogure; Keitetsu Abe; Nami Chiba; Shigeo Tsukahara
Journal:  Jpn J Ophthalmol       Date:  2004 Mar-Apr       Impact factor: 2.447

View more
  6 in total

1.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

2.  Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.

Authors:  Takaiko Yoshino; Takeo Fukuchi; Tetsuya Togano; Masaaki Seki; Hiroko Ikegaki; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

3.  A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.

Authors:  Daniel M Albert; Ronald E Gangnon; Hans E Grossniklaus; W Richard Green; Soesiawati Darjatmoko; Amol D Kulkarni
Journal:  Arch Ophthalmol       Date:  2008-05

4.  Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension.

Authors:  Kenji Inoue; Minako Shiokawa; Michitaka Sugahara; Risako Higa; Masato Wakakura; Goji Tomita
Journal:  Clin Ophthalmol       Date:  2012-01-12

Review 5.  Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.

Authors:  Murray Fingeret; Ian B Gaddie; Marc Bloomenstein
Journal:  Clin Exp Optom       Date:  2019-01-07       Impact factor: 2.742

6.  Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.

Authors:  Kazuhide Kawase; Jason L Vittitow; Robert N Weinreb; Makoto Araie
Journal:  Adv Ther       Date:  2016-07-25       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.